Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Imunomodulační léčba intersticiální plicní choroby spojené s variantami genů souvisejících s surfaktantem (TIPS)

17. září 2026 aktualizováno: Assistance Publique - Hôpitaux de Paris

Imunomodulační léčba intersticiálního plicního onemocnění spojeného s variantami genů souvisejících se surfaktantem

Scientific justification : Variants in surfactant-related genes (SRG) explain approximately 6% of familial pulmonary fibrosis (FPF).

The pathophysiology is unknown and seems to involve endoplasmic reticulum stress in type 2 alveolar epithelial cells.

Variable improvement in the prognosis of childhood and adult interstitial lung disease (ILD) associated with a variant of a SRG, initially reported to be lethal within months of diagnosis, has been observed since the consensual use of prednisone, azithromycin and hydroxychloroquine targeting endoplasmic reticulum stress, without demonstration of the efficacy of any of these treatments alone or in combination.

The investigators hypothesize that a treatment combining prednisone, azithromycin and hydroxychloroquine is safe and could improve the prognosis of adult patients with ILD associated with SRG variant.

Main objective and primary endpoint : Main objective:

Evaluate the efficacy of triple immunomodulatory therapy (prednisone, azithromycin and hydroxychloroquine) for 12 months in patients with ILD associated with a variant of a surfactant-related gene.

Primary endpoint:

Difference in forced vital capacity decline between the 2 groups at one year.

Secondary objectives and endpoints : Secondary objectives:

  1. tolerance of the triple therapy,
  2. correlation between the respiratory, radiological and clinical functional response,
  3. quality of life of the patients,
  4. overall survival, transplant-free survival, exacerbation free-survival, hospitalization-free survival

Secondary endpoints:

  1. Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (at 3, 6, 9, 12 months after randomization) (only HCQ or AZI patients) and ophthalmological (at one year after randomization)
  2. Thoracic CT scan and PFT at 6 months and one year after randomization
  3. Quality of life questionnaire (EORTC QLQ-C30, v3.0) at 3 months, 6 months, 9 months and one year after randomization,
  4. Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization.

Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care

Category : Category 2

Population of study participants: Patients aged over 18 years with ILD and SRG variant

Number of participants included : 30

Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

30

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

Studijní místa

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 80 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Age ≥ 18 years and <80 years
  2. Carrier of a variant classified as pathogenic or probably pathogenic or considered as eligible by the genetic multidisciplinary discussion in SFTPA1, SFTPA2, SFTPC, NKX2-1, SFTPB or two variants classified as pathogenic or probably pathogenic or considered as eligible by the genetic multidisciplinary discussion in ABCA3 or SFTPB
  3. ILD whatever the pattern corresponding to a volume > 10% of the total lung on a CT scan of less than 2 years

Exclusion Criteria:

  1. Contraindication to azithromycin and hydroxychloroquine and prednisone (details in section 6.2)
  2. Pregnancy and breastfeeding
  3. Female of childbearing potential* not willing to use reliable contraception from inclusion and during 22 months
  4. Desire to have a child within 22 months
  5. Enrolment to another interventional study (clinical trial on medicinal product, medical device and interventional research involving human participants not concerning health product)
  6. Subject deprived of their liberty or subject that may have insufficient power, intelligence, education, resources, strength, or other needed attributes to protect their own interests; or unable to explicitly give consent.
  7. No affiliation to any health insurance system
  8. Refusal to participate to the study

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Prednisone 10 mg/day -Hydroxychloroquine 400 mg/day - Azithromycin 250mg*3

The experimental treatment will be the combination of:

  • Prednisone 10 mg/day (1 tablet/day)
  • Hydroxychloroquine 400 mg/day (2 tablets/day)
  • Azithromycin 250 mg x3/week (3 tablets/week) Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no

Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no

Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no

Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no

Aktivní komparátor: Standard of care

Standard of care: any symptomatic treatment to interstitial lung disease. No other experimental or off-label treatment (such as ivacaftor) will be allowed during the study.

Standard of care: any symptomatic treatment to interstitial lung disease. No other experimental or off-label treatment (such as ivacaftor) will be allowed during the study.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Difference in forced vital capacity decline between the 2 groups at one year.
Časové okno: 12 Months

Evaluate the efficacy of triple immunomodulatory therapy (prednisone, azithromycin and hydroxychloroquine) for 12 months in patients with ILD associated with a variant of a surfactant-related gene.

12 Months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
tolerance of the triple therapy
Časové okno: 12 months

Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) (at 3, 6, 9, 12 months after randomization) (only HCQ or AZI patients) and ophthalmological (at 6 months and 12 months after randomization)

12 months
correlation between the respiratory, radiological and clinical functional response,
Časové okno: 12 months

Thoracic CT scan (progression criteria [99]) and PFT (Pulmonary function tests) at one year after randomization

12 months
Quality of life of the patients
Časové okno: 12 months

Quality of life questionnaire (SF-36, scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 : a validated patient-reported questionnaire for assessing quality of life in cancer patients.) at one year after randomization,

12 months
tolerance of the triple therapy
Časové okno: 6 months

Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) at 6, months after randomization (only HCQ or AZI patients) and ophthalmological (at one year after randomization)

6 months
tolerance of the triple therapy
Časové okno: 3 months

Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) at 3 months after randomization (only HCQ or AZI patients) and ophthalmological (at one year after randomization)

3 months
correlation between the respiratory, radiological and clinical functional response,
Časové okno: 6 months

Thoracic CT scan (progression criteria [99]) and PFT (Pulmonary function tests) at 6 months after randomization

6 months
Quality of life of the patients
Časové okno: 9 months

Quality of life questionnaire (SF-36,scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 : a validated patient-reported questionnaire for assessing quality of life in cancer patients.) at 9 months after randomization,

9 months
Quality of life of the patients
Časové okno: 6 months

Quality of life questionnaire (SF-36 scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 :a validated patient-reported questionnaire for assessing quality of life in cancer patients. ) at 6 months after randomization,

6 months
Quality of life of the patients
Časové okno: 3 months

Quality of life questionnaire (SF-36, scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 :a validated patient-reported questionnaire for assessing quality of life in cancer patients ) at 3 months after randomization,

3 months
Overall survival
Časové okno: 12 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization

12 months
Transplant-free survival
Časové okno: 12 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization

12 months
Exacerbation free-survival
Časové okno: 12 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization

12 months
Hospitalization-free survival
Časové okno: 12 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization

12 months
tolerance of the triple therapy
Časové okno: 9 months

Clinical and biological tolerance (occurrence of an adverse effect during treatment),

9 months
tolerance of the triple therapy
Časové okno: 12 months

ECG (including QTc prolongation) at 12 months after randomization (only HCQ or AZI patients)

12 months
tolerance of the triple therapy
Časové okno: 12 months

Ophthalmological (at one year after randomization)

12 months
tolerance of the triple therapy
Časové okno: 9 months

ECG (including QTc prolongation) at , 9 months after randomization (only HCQ or AZI patients)

9 months
tolerance of the triple therapy
Časové okno: 6 months

ECG (including QTc prolongation) at 6 months after randomization (only HCQ or AZI patients)

6 months
tolerance of the triple therapy
Časové okno: 3 months

ECG (including QTc prolongation) at 3 months after randomization (only HCQ or AZI patients)

3 months
Overall survival
Časové okno: 9 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 9 months after randomization

9 months
Overall survival
Časové okno: 6 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 6 months after randomization

6 months
Overall survival
Časové okno: 3 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 3 months after randomization

3 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. listopadu 2026

Primární dokončení (Odhadovaný)

1. listopadu 2027

Dokončení studie (Odhadovaný)

1. listopadu 2027

Termíny zápisu do studia

První předloženo

11. února 2026

První předloženo, které splnilo kritéria kontroly kvality

27. února 2026

První zveřejněno (Aktuální)

2. března 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

22. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

17. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • APHP251230

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .